Labiana Health, S.A. (LAB.MC)
MCE · EUR · Healthcare · Drug Manufacturers - Specialty & Generic
€5.30 (-3.64%) as of
Key statistics
- Market cap
- 44.99M
- P/E (TTM)
- 15.14
- Forward P/E
- 5.45
- EPS (TTM)
- 0.35
- Dividend yield
- 0.00%
- 52-week range
- 4.04 – 8.20
- Beta
- 0.20
- Revenue (TTM)
- 76.44M
- Profit margin
- 3.36%
- Analyst target
- €9.50
- Volume
- 1.07k
About Labiana Health, S.A.
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, it offers contract development and manufacturing services. The company was founded in 1958 and is based in Pozuelo de Alarcón, Spain.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Pozuelo de Alarcón, Spain
- Employees
- 373
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.